| Literature DB >> 33266287 |
Martin Eichler1,2, Leopold Hentschel2, Stephan Richter1, Peter Hohenberger3, Bernd Kasper4, Dimosthenis Andreou5,6, Daniel Pink6,7, Jens Jakob8, Susanne Singer9, Robert Grützmann10, Stephen Fung11, Eva Wardelmann12, Karin Arndt13, Vitali Heidt14, Christine Hofbauer2,15, Marius Fried16, Verena I Gaidzik17, Karl Verpoort18, Marit Ahrens19, Jürgen Weitz2,20, Klaus-Dieter Schaser2,15, Martin Bornhäuser1,2, Jochen Schmitt2,21, Markus K Schuler1,22.
Abstract
Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60-66%), physical (60%, 95% CI 57-62%), role functioning (51%, 95% CI 48-54%), and pain (56%, 95% CI 53-59%) and fatigue (51%, 95% CI 48-54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.Entities:
Keywords: clinically important restrictions and symptoms; health-related quality of life; observational study; rare disease; sarcoma
Year: 2020 PMID: 33266287 DOI: 10.3390/cancers12123590
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.639